Alto Neuroscience (NYSE:ANRO) Shares Gap Down – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $29.54, but opened at $27.10. Alto Neuroscience shares last traded at $26.2850, with a volume of 18,321 shares changing hands.

Trending Headlines about Alto Neuroscience

These are some of the ANRO headlines that stood out recently:

  • Positive Sentiment: Alto reported a quarterly loss of $0.54 per share, narrower than analysts’ $0.67 loss estimate. The earnings beat may offer support, although the loss widened year over year. Alto Neuroscience quarterly loss and valuation analysis
  • Neutral Sentiment: An analysis questioned whether ANRO’s premium valuation is justified, underscoring valuation risk without identifying a new company-specific catalyst. Alto Neuroscience valuation analysis
  • Negative Sentiment: COO Michael Hanley sold 70,000 shares on November 16 and made additional sales of 2,896 and 2,104 shares over the following two days. The sales substantially reduced his reported stake and may weigh on sentiment, though insider transactions alone do not establish the company’s outlook. Alto Neuroscience COO share sales

Analyst Ratings Changes

ANRO has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. Wedbush increased their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a report on Thursday, November 12th. Finally, Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.88.

Read Our Latest Stock Analysis on Alto Neuroscience

Alto Neuroscience Stock Up 3.4%

The company has a quick ratio of 18.12, a current ratio of 18.12 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average is $25.83 and its two-hundred day moving average is $24.79.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13. Analysts predict that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current fiscal year.

Insider Transactions at Alto Neuroscience

In other Alto Neuroscience news, COO Michael Hanley sold 2,896 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $26.48, for a total transaction of $76,686.08. Following the transaction, the chief operating officer owned 17,729 shares in the company, valued at approximately $469,463.92. This represents a 14.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Nicholas Smith sold 24,056 shares of the company’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the completion of the transaction, the chief financial officer directly owned 24,060 shares in the company, valued at approximately $621,229.20. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 209,886 shares of company stock worth $5,637,703 in the last 90 days. Insiders own 11.25% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Commodore Capital LP boosted its stake in shares of Alto Neuroscience by 49.4% during the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after acquiring an additional 900,000 shares in the last quarter. Perceptive Advisors LLC increased its stake in shares of Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Spruce Street Capital LP increased its stake in shares of Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares in the last quarter. Bellevue Group AG acquired a new position in Alto Neuroscience in the 3rd quarter worth about $29,706,000. Finally, Marshall Wace LLP raised its holdings in Alto Neuroscience by 281.1% in the 3rd quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock worth $21,938,000 after purchasing an additional 633,806 shares during the period.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Further Reading

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.